TRUMF:OTC-Terumo Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 18.234

Change

-1.19 (-6.15)%

Market Cap

USD 29.21B

Volume

997.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 108.14B
ESLOY Essilor International SA

N/A

USD 106.30B
HOCPF HOYA Corporation

N/A

USD 49.96B
HOCPY Hoya Corp

N/A

USD 49.96B
CLPBY Coloplast A

-0.16 (-1.23%)

USD 29.67B
CLPBF Coloplast A/S

N/A

USD 29.67B
SAUHF Straumann Holding AG

N/A

USD 26.17B
OCPNF Olympus Corporation

N/A

USD 22.43B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.85B
SDMHF Sartorius Stedim Biotech S.A

-17.55 (-8.24%)

USD 20.72B

ETFs Containing TRUMF

DXJH 0.00 % 0.48 %

N/A

N/A
CNKY:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

+217.00 (+0.08%)

USD 55.85B
XDJP:LSE Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+23.50 (+0.08%)

N/A
SXRZ:F iShares VII PLC - iShares.. 0.00 % 0.00 %

+4.25 (+0.08%)

USD 57.94B
EXX7:XETRA iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

+0.31 (+0.08%)

USD 28.25B
SXRZ:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

+3.25 (+0.08%)

USD 58.15B
XDJE:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+1.14 (+0.08%)

USD 0.03B
XDJP:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+0.34 (+0.08%)

USD 157.79B
1329:TSE iShares Core Nikkei 225 E.. 0.00 % 0.00 %

+50.00 (+0.08%)

USD 1,529.93B
1330:TSE Nikko Nikkei 225 Listed 0.00 % 0.00 %

+50.00 (+0.08%)

USD 5,423.56B
1369:TSE DIAM Nikkei 225 0.00 % 0.00 %

+50.00 (+0.08%)

USD 451.27B
1578:TSE Listed Index Fund Nikkei .. 0.00 % 0.00 %

+5.00 (+0.08%)

USD 12.13B
1397:TSE SMDS SMDAM NIKKEI225 ETF 0.00 % 0.00 %

+30.00 (+0.08%)

USD 195.63B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.74% 71% C- 67% D+
Dividend Return 138.72% 96% N/A 99% N/A
Total Return 153.46% 98% N/A 94% A
Trailing 12 Months  
Capital Gain 42.68% 83% B 80% B-
Dividend Return 172.50% 96% N/A 99% N/A
Total Return 215.18% 97% N/A 96% N/A
Trailing 5 Years  
Capital Gain 17.22% 62% D 68% D+
Dividend Return 240.50% 94% A 98% N/A
Total Return 257.72% 98% N/A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 0.39% N/A N/A 40% F
Dividend Return 37.63% N/A N/A 72% C
Total Return 37.24% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 49.92% N/A N/A 51% F
Risk Adjusted Return 75.37% N/A N/A 95% A
Market Capitalization 29.21B 89% A- 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.